GGrantIndex
← Leaderboards

Srinivas R Sadda

Doheny Eye Institute

$2,836,779
Attributed
$6,165,805
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,165,805 · 6

By mechanism

R01$4,252,872 · 3
R21$1,912,933 · 3

Most similar at Doheny Eye Institute

Same institution · by research overlap

Others in their field

Top investigators on “Blindness

Research focus

BlindnessImagePhenotypeRetinaHigh RiskRisk FactorsClinical TrialsAge Related Macular DegenerationColorClinical ResearchFundusClinicVisitClinical PracticeOptical Coherence TomographyMaculaStagingAtrophicDeep LearningBaseResearch PersonnelTherapeutic TrialsRetinal DiseasesElderly

Grant awards (16)

Epidemiology of Biomarkers of AMD Progression$588,379
R01 · FY2025 · EY · contact PI
In vivo Imaging of the Human Retina at the Molecular Level$514,294
R01 · FY2025 · EY · contact PI
Epidemiology of Biomarkers of AMD Progression$585,469
R01 · FY2024 · EY · contact PI
In vivo Imaging of the Human Retina at the Molecular Level$532,924
R01 · FY2024 · EY · contact PI
Epidemiology of Biomarkers of AMD Progression$582,584
R01 · FY2023 · EY · contact PI
Epidemiology of Biomarkers of AMD Progression$640,560
R01 · FY2021 · EY · contact PI
Artificial Intelligence for Assessment of Stargardt Macular Atrophy$190,362
R21 · FY2021 · EY
Artificial Intelligence for Assessment of Stargardt Macular Atrophy$235,500
R21 · FY2020 · EY
Discovery and Validation of AMD Biomarkers for Progression Using Deep Learning$196,250
R21 · FY2020 · EY
Discovery and Validation of AMD Biomarkers for Progression Using Deep Learning$235,500
R21 · FY2019 · EY
Genetic Susceptibility for Development of Proliferative Diabetic Retinopathy$396,581
R01 · FY2010 · EY · contact PI
Genetic Susceptibility for Development of Proliferative Diabetic Retinopathy$412,081
R01 · FY2009 · EY · contact PI
Objective Diagnosis & Quantification of Retinal Disease$342,030
R21 · FY2007 · EY · contact PI
Objective Diagnosis & Quantification of Retinal Disease$352,681
R21 · FY2006 · EY · contact PI
Objective Diagnosis &Quantification of Retinal Disease$172,840
R21 · FY2005 · EY
Objective Diagnosis &Quantification of Retinal Disease$187,770
R21 · FY2004 · EY